TY - JOUR
T1 - Synergistic effect of tolfenamic acid and glycyrrhizic acid on TPA-induced skin inflammation in mice
AU - Liu, Wenfeng
AU - Huang, Shun
AU - Li, Yonglian
AU - Zheng, Xi
AU - Zhang, Kun
N1 - Funding Information:
Financial support was provided by the funds of the Science Foundation for Young Teachers of Wuyi University (No: 2016zk04 and 2017td01), the Foundation for Young Talents (No: 2016KQNCX174, 2017GkQNCX006 and 2017KTSCX184), the Doctor Start-up Funds of Wuyi University (No: 2016BS19), the Basic and Theoretical Research Programs of Science and Technology Foundation of Jiangmen, Self-financing Science and Technology Foundation of Foshan (No: 2017AB000202), the President Foundation Project of Nanfang Hospital, Southern Medical University (No: 2018Z003) and the Foundation for Department of Education of Guangdong Province (No: 2016KCXTD005, 2017KSYS010 and 2017KZDXM084). Dr. Xi Zheng is the Unilever Chair in Nutrition and Disease Prevention Research at Rutgers University.
Publisher Copyright:
This journal is © The Royal Society of Chemistry.
PY - 2019
Y1 - 2019
N2 - Tolfenamic acid (TA) and glycyrrhizic acid (GA) are well-known components with anti-inflammatory properties. However, their combined effects on inflammation have not been well studied. The present study aimed to investigate the in vivo anti-inflammatory effects of TA combined with GA using a 12-O-Tetradecanoylphorbol-13-Acetate (TPA)-induced mouse ear edema model, as well as the underlying mechanisms thereof. The results indicated that TA combined with GA led to a stronger inhibition on TPA-induced mouse ear edema compared to the singular treatments. In addition, the combined treatment significantly alleviated subcutaneous tissue inflammation caused by TPA. Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Furthermore, the combined treatment effectively inhibited nuclear factor-κB (NF-κB), extracellular signal-regulated kinase (ERK1/2), c-Jun N-Terminal kinase (JNK), phosphor-ERK1/2 and phosphor-JNK, which was accompanied by blocking of the activation and the phosphorylation in mitogen-Activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt signaling pathways. Collectively, our findings revealed that different anti-inflammatory components used in combination lead to enhanced inhibitory effects against inflammation.
AB - Tolfenamic acid (TA) and glycyrrhizic acid (GA) are well-known components with anti-inflammatory properties. However, their combined effects on inflammation have not been well studied. The present study aimed to investigate the in vivo anti-inflammatory effects of TA combined with GA using a 12-O-Tetradecanoylphorbol-13-Acetate (TPA)-induced mouse ear edema model, as well as the underlying mechanisms thereof. The results indicated that TA combined with GA led to a stronger inhibition on TPA-induced mouse ear edema compared to the singular treatments. In addition, the combined treatment significantly alleviated subcutaneous tissue inflammation caused by TPA. Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Furthermore, the combined treatment effectively inhibited nuclear factor-κB (NF-κB), extracellular signal-regulated kinase (ERK1/2), c-Jun N-Terminal kinase (JNK), phosphor-ERK1/2 and phosphor-JNK, which was accompanied by blocking of the activation and the phosphorylation in mitogen-Activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt signaling pathways. Collectively, our findings revealed that different anti-inflammatory components used in combination lead to enhanced inhibitory effects against inflammation.
UR - http://www.scopus.com/inward/record.url?scp=85073807795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073807795&partnerID=8YFLogxK
U2 - 10.1039/c9md00345b
DO - 10.1039/c9md00345b
M3 - Article
AN - SCOPUS:85073807795
SN - 2040-2503
VL - 10
SP - 1819
EP - 1827
JO - MedChemComm
JF - MedChemComm
IS - 10
ER -